- By ICR Secretariat
- Posted Friday, March 8, 2019
EU Regulatory Roundup: Germany Warns Brexit Could Cause the Suspension of 1,300 Clinical Trials
Germany’s Federal Institute for Drugs and Medical Devices (BfArM) has warned that it could suspend 1,300 clinical trials in the event of a no-deal Brexit. The warning reflects the fact that the sponsors of many studies are still registered in the UK and there are stipulations in the Medicinal Products Act (AMG) about who can run trials in Germany.